The first patient has been dosed with PFL-002/VERT-002 in a Phase I/II first-in-human trial for patients with non-small cell lung cancer (NSCLC) with MET alterations.

PFL-002/VERT-002 is a monoclonal antibody acting as a degrader of c-MET.

MET, also known as hepatocyte growth factor receptor (HGFR), is an oncogene driver in subsets of patients suffering from NSCLC.

MET exon 14 skipping mutation and MET amplification are found as primary oncogenic drivers and MET amplification as a resistance mechanism to selected targeted therapies.

“PFL-002/VERT-002 targets a clinically validated oncogenic driver with a unique and differentiated mechanism of action, triggering the degradation of the c-MET oncogene. Thus, it provides the opportunity to test a novel therapeutic approach for patients with MET driven tumours. We are looking forward to collaborating with the investigators participating in the first-in-human trial to assess the safety and efficacy of this new agent,” said Francesco Hofmann, Head of Research and Development for Medical Care at Pierre Fabre Laboratories.

MET TKIs (tyrosine kinase inhibitors) are approved therapeutic options for the treatment of NSCLC with MET exon 14 skipping mutation. However, there is no approved MET targeted therapy for patients presenting with MET amplification.

PFL-002/VERT-002 was originally developed by Vertical Bio, which has been acquired by Pierre Fabre Laboratories.

Pierre Fabre has recently added several assets to its R&D pipeline for solid tumours. In partnership with Scorpion Therapeutics, PFL-241/STX-241 and PFL-721/STX-721, two mutant-selective EGFR inhibitors, will be developed for the treatment of EGFR-driven non-small cell lung cancer (NSCLC) patients.

More recently, the pan-RAF inhibitor exarafenib was acquired from Kinnate Biopharma with the aim to expand targeted therapy options for RAS/RAF-driven solid tumours.

Diana Spencer, Senior Digital Content Editor, DDW